Affordable Access

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.

Authors
  • Hommes, D W
  • Mikhajlova, T L
  • Stoinov, S
  • Stimac, D
  • Vucelic, B
  • Lonovics, J
  • Zákuciová, M
  • D'Haens, G
  • Van Assche, G
  • Ba, S
  • Lee, S
  • Pearce, T
Type
Published Article
Journal
Gut
Publication Date
Aug 01, 2006
Volume
55
Issue
8
Pages
1131–1137
Identifiers
PMID: 16507585
Source
Medline
License
Unknown

Abstract

Treating active CD with fontolizumab was well tolerated and resulted in increased rates of clinical response and remission compared with placebo.

Report this publication

Statistics

Seen <100 times